Sirtex Medical Acquires FDA-Cleared Vascular Device to Expand Minimally Invasive Treatment Portfolio

0
14
Dr. Gary Siskin

WOBURN, Mass.–Sirtex Medical has acquired the Hourglass Vascular Plug, an FDA-cleared medical device designed to control blood flow in peripheral blood vessels, expanding the company’s portfolio of minimally invasive embolization technologies.

The acquisition adds another vascular treatment option to Sirtex’s existing product lineup, which includes the LAVA Liquid Embolic System. Financial terms of the transaction were not disclosed.

The Hourglass Vascular Plug is designed to obstruct or reduce blood flow in peripheral vessels measuring 6 to 8 millimeters in diameter. The device received 510(k) clearance from the U.S. Food and Drug Administration in 2017.

Embolization is a minimally invasive medical procedure in which physicians intentionally block or reduce blood flow to targeted areas of the body. The technique is used in interventional radiology and other specialties to treat a range of vascular conditions.

The Hourglass device was previously introduced in the United States through a limited market release. Sirtex is now completing preparations to make the technology more widely available to physicians, with additional information about commercial availability expected to be provided to customers.

Dr. Gary Siskin, Professor and Chair of Radiology at Albany Medical Center and a Fellow of the Society of Interventional Radiology, said the device could provide physicians with another option for performing embolization procedures.

“Dependable occlusion tools are central to treating a growing range of conditions with embolization. My experience with Hourglass was very positive, and I look forward to this device being available to physicians and their patients,” said Siskin.

Sirtex specializes in interventional oncology and embolization technologies, developing medical devices used in minimally invasive procedures.

The addition of Hourglass is intended to complement the company’s existing embolization products and expand the range of tools available to interventional specialists.

“Behind every embolization procedure is a patient who benefits from a less invasive path to treatment,” said Matt Schmidt, Chief Executive Officer of Sirtex Medical. “Our investment in Hourglass is about making sure the physicians we work with have the right tools to deliver that care.”

Sirtex has not announced a specific date for the broader commercial availability of the Hourglass Vascular Plug.

Leave A Reply

Please enter your comment!
Please enter your name here